Pharmaceuticals

This channel includes news and new technology innovations for cardiovascular pharmaceutics. This includes antiplatelet agents, anticoagulation drugs, INR testing, NOAC, OAC, IV administered drugs such as Heprin, and dual antiplatelet therapy.

Prescribing Patterns Change Following Direct Marketing Restrictions
News | Pharmaceuticals | May 05, 2017

May 5, 2017 — A study of how policies restricting...

An electrophysiology EP ablation procedure to treat a heart arrhythmia
Feature | HRS | May 16, 2017

May 16, 2017 — Here is a list of the late-breaking clinical trials presented at the Heart Rhythm Society (HRS) 2017...

EBBINGHAUS study, evolocumab, repatha, statin therapy, cognitive issues, ACC.17 study
News | Pharmaceuticals | April 03, 2017

April 3, 2017 — There is no evidence that adding a new...

Ablation procedure, EP lab, Uninterrupted Dabigatran Etexilate in Comparison to Uninterrupted Warfarin in Pulmonary Vein Ablation
Feature | Atrial Fibrillation | March 29, 2017

March 29, 2017 — Uninterrupted treatment with dabigatran (Pradaxa), a non-vitamin K,...

synthetic HDL-C injection, cholesterol, arterial plaque, heart attack patients, CARAT trial, ACC.17, clinical study
News | Pharmaceuticals | March 29, 2017

March 29, 2017 — Injection of a novel form of synthetic high-density lipoprotein cholesterol (HDL-C), or good...

PCI, drugs, medication, fully blocked arteries, chronic total occlusion, ACC.17, clinical study
News | Chronic Total Occlusion (CTO) | March 29, 2017 | Dave Fornell

March 29, 2017 — In patients with a complete, persistent arterial blockage, medication alone was found to be equal...

heart-lung machine, ECMO, levosimendan, heart failure drug, cardiovascular surgery outcomes, ACC.17 study
News | Pharmaceuticals | March 28, 2017

March 28, 2017 — When used as a preventive measure during heart surgery, the heart failure...

ECRI Institute, top 10 patient safety concerns, 2017 report, information technology, healthcare
News | Information Technology | March 24, 2017

March 24, 2017 — Safe implementation of...

bleeding complications, rivaroxaban, antiplatelet therapy, post-ACS, acute coronary syndrome, ACC.17 study
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — Bleeding complications did not increase for patients with acute coronary syndrome treated with...

rivaroxaban, asprin, venous thromboembolism, VTE recurrence, clinical study, ACC.17
News | Antiplatelet and Anticoagulation Therapies | March 23, 2017

March 23, 2017 — In patients at elevated risk for a recurrence of potentially life- threatening blood clots, a low...

PCSK9 inhibitors, bococizumab, ACC .17, clinical trials, LDL cholesterol
News | Pharmaceuticals | March 22, 2017

March 22, 2017 — In a clinical program that was terminated early, the experimental PCSK9 inhibitor bococizumab, when...

RESOLVE study, RESOLVE trial, subclinical leaflet thrombosis

A CT study from the RESOLVE Trial showing valve leaflet thrombosis on a TAVR device. The trial examined a range of surgical and transcatheter valves to show thrombosis is found across both types of devices. It also examined if anticoagulation or antiplatelet therapy could reduce thrombosis and allow a greater range of leaflet motion.

Feature | Heart Valve Technology | March 21, 2017

March 21, 2017 — About 12 percent of patients undergoing aortic valve replacement developed non-symptomatic blood...

Evolocumab, Repatha, LDL, ACC late breaker, best LDL lowering drug
Feature | Pharmaceuticals | March 20, 2017

March 20, 2017 — The most important late-breaking pharmaceutical trial at the 2017 America College of Cardiology...

warfarin, anticoagulation therapy, atrial fibrillation patients, Duke Clinical Research Institute study, stroke
News | Antiplatelet and Anticoagulation Therapies | March 14, 2017

March 14, 2017 — More than 80 percent of stroke patients with a history of...

Overlay Init